Literature DB >> 16120090

A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions.

P Wu1, S Mitchell, G M Walsh.   

Abstract

BACKGROUND: We previously demonstrated that low concentrations of a new antihistamine levocetirizine inhibited eosinophil transmigration through human microvascular endothelial cells.
OBJECTIVE: Here, the inhibitory effect of levocetirizine on eosinophil adhesion to recombinant human vascular cell adhesion molecule-1 (rhVCAM)-1 was examined under conditions of shear stress using an in vitro model of the post-capillary venules.
METHODS: Eosinophils isolated from normal subjects were pre-incubated with a concentration range of levocetirizine (10(-6)-10(-10) m) or negative dilution control. Resting or granulocyte macrophage-colony stimulating factor (GM-CSF)-stimulated cells were pumped through rhVCAM-1 (10 microg/mL) coated capillary tubes using a microfluidic syringe pump at a precise and constant flow rate (1 dyn/cm(2)). Images of rolling and firmly adherent eosinophils were captured using real-time video microscopy.
RESULTS: Levocetirizine significantly inhibited resting eosinophil adhesion to rhVCAM-1 with maximal effect at 10(-8) M with an EC(50) of 10(-9) m. Levocetirizine almost abolished resting eosinophil adhesion by the 15 min time-point. GM-CSF significantly enhanced eosinophil adhesion and their ability to flatten on rhVCAM-1. Both phenomena were inhibited by levocetirizine in a dose-dependent manner, at both 5 and 15 min (optimal concentration of 10(-8) m with an EC(50) of 10(-9) m). Real-time imaging revealed that the effect of levocetirizine on post-adhesion behaviour (detachment, flatness) contributed to its inhibitory action on eosinophil adhesion to rhVCAM-1. In contrast, very late antigen (VLA)-4 mAb inhibited eosinophil adhesion to rhVCAM-1 from the earliest time-points.
CONCLUSION: Physiologically relevant concentrations of levocetirizine inhibit resting and GM-CSF-stimulated firm eosinophil adhesion to rhVCAM-1 under flow conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16120090     DOI: 10.1111/j.1365-2222.2005.02290.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

1.  Molecular Biology of Eosinophils: Introduction.

Authors:  Paige Lacy; Helene F Rosenberg; Garry M Walsh
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies.

Authors:  Philip I Hair; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety.

Authors:  P Anuradha; Rituparna Maiti; J Jyothirmai; Omer Mujeebuddin; M Anuradha
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

Review 4.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series].

Authors:  S Schulz; M Metz; D Siepmann; T A Luger; M Maurer; S Ständer
Journal:  Hautarzt       Date:  2009-07       Impact factor: 0.751

6.  Therapeutic targeting of eosinophil adhesion and accumulation in allergic conjunctivitis.

Authors:  Monica Baiula; Andrea Bedini; Gioia Carbonari; Samantha Deianira Dattoli; Santi Spampinato
Journal:  Front Pharmacol       Date:  2012-12-26       Impact factor: 5.810

7.  Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria.

Authors:  E Nettis; G F Calogiuri; E Di Leo; F Cardinale; L Macchia; A Ferrannini; A Vacca
Journal:  J Asthma Allergy       Date:  2008-12-16

8.  The anti-inflammatory effects of levocetirizine--are they clinically relevant or just an interesting additional effect?

Authors:  Garry M Walsh
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-17       Impact factor: 3.406

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.